Syne qua non and uMotif partner to bring next-generation patient-centric data capture technology to clinical trial sponsors
Syne qua non (SQN), the award-winning biometrics CRO have signed a new partnership with uMotif, a company delivering the leading next-generation patient data capture platform, to provide clinical trial sponsors with patient-centric technology for trials of all phases, including Real-World Evidence.
This partnership offers sponsors new ways to put patients at the center of clinical trials – improving trial recruitment, patient retention, efficiency and data capture through digital tools trial participants love to use.
Clinical development is the most time intensive and expensive part of new drug research and development representing an average $0.5 to $0.9 billion cost as part of bringing a new therapy to market. Pharmaceutical and medtech companies at the heart of the global clinical development and clinical trials market are rapidly adopting patient-centric technologies and processes. Regulators and pricing bodies are increasingly requiring the capture and reporting of patient reported data – eCOA / ePRO – in clinical and commercial phase research, to ensure that patient’s voices are heard in research.
The new partnership offers sponsors new ways to engage patients and capture a wide range of data tailored to each study protocol, including eCOA and ePRO instruments, symptoms, wearable device data and flexible e-diaries.
Tony Rees, Director of SQN said:
“This is an exciting collaboration and allows us to enhance delivery on what clients and regulatory agencies are now asking for. This augments SQN’s award winning EDC and trial management system with one of the most advanced patient centric data collection systems on the market. uMotif is the leader in this new wave of patient centric and clinical trials innovation, and the only platform clinically proven in the UK NHS and we are delighted to partner with them.”
Bruce Hellman, CEO of uMotif said:
“We’re delighted to be working with SQN, who share our passion for innovative and high quality data capture, important in clinical research, through tools that patients love to use, that encourages compliance and their continued clinical trial engagement. Putting patients at the heart of research delivers real value to sponsors across the world – and working with SQN we’re now able to rapidly grow to take our technology to more studies, in more therapeutic areas and geographies including the USA.”
SQN is one of the market leaders in specialist clinical trial biometrics, established for over 20 years. Their CRO services include biostatistics, EDC, project and data management, study setup and management, and other clinical services. SQN has worked with 7 of the top 10 pharma and biotech companies with broad therapeutic expertise notably in Oncology, Rare Diseases, personalized medicine and other complex indications, SQN will incorporate uMotif’s technology into a seamless data capture, trial management, and reporting process.
Founded in 2012, uMotif have built a validated cloud-based technology platform for the capture of patient-generated data and are working with organisations including AstraZeneca, UCB Pharma, QuintilesIMS and Merck. The uMotif platform has captured over 64 million data points from 18,000 patients – all having provided in-app e-consent on their own smartphone and tablet devices (Bring Your Own Device – BYOD). uMotif’s patient-centric design has been proven in leading hospitals and academic studies across the world, including the only published successful NHS trial of a smartphone app in npj Parkinson’s Disease journal.
The partners’ combined technologies and services are available now for inclusion in any clinical study across all phases and therapeutic indications.